Journal of Psychopharmacology

Journal of Psychopharmacology is a monthly peer-reviewed journal published by SAGE since 1987 as the official journal of the British Association for Psychopharmacology, covering preclinical and clinical psychopharmacology, with a 2025 Journal Impact Factor of 5.3.《精神药理学杂志》（Journal of Psychopharmacology）由（SAGE）出版，1987 年创刊，是英国精神药理学协会（BAP）的官方期刊，按月发行，涵盖精神药理学的临床前与临床研究，2025 年影响因子为 5.3。

Scope

• Preclinical psychopharmacology, including behavioural pharmacology studies in animals临床前精神药理学，包括动物行为药理学研究。
• Clinical psychopharmacology and trials of psychotropic drugs in psychiatric and neurological disorders临床精神药理学，以及精神药物在精神与神经疾病中的临床试验。
• Effects of drugs on human behaviour, mood and cognition药物对人类行为、情绪与认知的影响。
• Mechanisms of drug action, from receptor pharmacology to systems neuroscience药物作用机制，从受体药理学到系统神经科学。
• Evidence-based guidelines and consensus statements issued by the British Association for Psychopharmacology英国精神药理学协会发布的循证指南与共识声明。
• Reviews, perspectives and debate on the drug treatment of mental disorders精神疾病药物治疗的综述、观点与争鸣。

History

• The journal was established in 1987, when its first volume appeared, as the official journal of the British Association for Psychopharmacology该刊于 1987 年创刊并出版第 1 卷，是英国精神药理学协会的官方期刊。
• It is published monthly, 12 issues a year, by SAGE Publications in London, under print ISSN 0269-8811 and online ISSN 1461-7285该刊由（SAGE Publications）在伦敦出版，每年 12 期，纸本 ISSN 为 0269-8811，网络 ISSN 为 1461-7285。
• David Nutt of Imperial College London edited the journal for more than two decades（Imperial College London）的 David Nutt 曾主持该刊编辑工作二十余年。
• The editorial process is run by the editors and is independent of both SAGE and the society, and the journal is a member of the Committee on Publication Ethics编辑流程由主编团队独立运作，不受（SAGE）与学会干预，期刊亦是出版伦理委员会（COPE）成员。
• It is a hybrid journal, with subscription content plus an open-access option for individual articles该刊为混合期刊，以订阅内容为主，单篇论文可选择开放获取。
• Its Journal Impact Factor moved from 4.153 in 2021 and 4.562 in 2022 to 5.5 in 2024 and 5.3 in 2025, placing it in the first quartile of psychiatry, clinical neurology, pharmacology and neuroscience其影响因子由 2021 年的 4.153、2022 年的 4.562 变为 2024 年的 5.5 与 2025 年的 5.3，在精神病学、临床神经病学、药理学与神经科学四个类别中均居第一四分位。

Editors

• The editors are Allan H Young, listed with King's College London and now head of the Department of Brain Sciences at Imperial College London, and Pierre Blier of the University of Ottawa in Canada现任主编为 Allan H Young 与（University of Ottawa）的 Pierre Blier，前者名录单位为（King's College London），现已出任（Imperial College London）脑科学系主任。
• Pallab Seth is managing editor, and the editorial office sits in the Neuropsychopharmacology Unit at the Hammersmith Hospital campus of Imperial College LondonPallab Seth 任执行编辑，编辑部设于（Imperial College London）哈默史密斯医院校区的神经精神药理学研究室。
• The editorial advisory board includes Ian Anderson of the University of Manchester, Simon Bate of GlaxoSmithKline, Theodora Duka of the University of Sussex, Barbara Sahakian of the University of Cambridge and Clare Stanford of University College London编辑顾问委员会包括（University of Manchester）的 Ian Anderson、（GlaxoSmithKline）的 Simon Bate、（University of Sussex）的 Theodora Duka、（University of Cambridge）的 Barbara Sahakian 与（University College London）的 Clare Stanford。
• The international editorial board draws members from Canada, the United States, Italy, Ireland, Sweden, Australia and New Zealand, among other countries国际编委来自加拿大、美国、意大利、爱尔兰、瑞典、澳大利亚与新西兰等国。
• Every submission is peer reviewed, and the journal publishes original research, reviews, editorials and letters所有投稿均经同行评审，刊物刊载原创研究、综述、社论与读者来信。